Recursion Pharmaceuticals Inc - Class A RXRX

NAS: RXRX | ISIN: DE0007201980 2/04/2026

3,110 USD (+1,63%)

(+1,63%) 2/04/2026

Grafiek Recursion Pharmaceuticals Inc - Class A

Grafiek Recursion Pharmaceuticals Inc - Class A

1 dag1d 1,63%
1 week1w 9,51%
1 maand1m -12,15%
3 maanden3m -28,83%
6 maanden6m -43,76%
1 jaar1j -25,95%
5 jaar5j -90,06%

Recursion Pharmaceuticals Inc - Class A in het nieuws

Toon enkel gratis nieuws

29 januari 2026 · AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift · Persbericht

30 juni 2025 · AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway · Persbericht

16 april 2025 · HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data · Persbericht

1 februari 2023 · Recursion to Participate in Upcoming Investor Conference · Persbericht

26 januari 2023 · Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day · Persbericht

20 december 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

8 november 2022 · Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results · Persbericht

2 november 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

25 oktober 2022 · Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB · Persbericht

13 september 2022 · Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe